Pfizer’s stock has dropped in the double digits over three years. The company faces declines in sales of its coronavirus products and the loss of exclusivity of other major products. But over ...

Pfizer offers a generous 5.73% dividend yield. The stock is trading at an attractive forward P/E of 9.5x 2026 earnings. The company has multiple potential growth drivers in its pipeline. Pfizer's ...

Pfizer stock (NYSE: PFE) is trading at about $30 per share, not far from the lows seen in recent years. Could the stock rise by over 2x in value over the next few years? Does this sound a bit ...

Pfizer’s transition from pandemic reliance to growth in oncology and rare diseases reflects a strategic pivot, supported by recent acquisitions, despite the challenge of rising debt ...

No large pharma company has traversed this decade's ups and downs quite like Pfizer. As the company rolls ahead with a large restructuring campaign, some staffers in Ireland will soon feel the ...

Pfizer (NYSE: PFE) has been around for 175 years, selling a wide range of drugs in various treatment areas over time. But this pharma giant truly became a household name a few years ago.

Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.

(Bloomberg) -- Pfizer Inc. has raised about £2.4 billion ($3.2 billion) from the sale of Haleon Plc shares, as it further reduces its stake in the UK consumer health company. The US ...

Pfizer's acquisition of Seagen for $43 billion enhances its ADC technology, potentially expanding its oncology franchise and driving future growth. PFE's development of the oral GLP-1 receptor ...

Sept 26 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks ...

Beata Zawrzel / NurPhoto via Getty Images Pfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of safety concerns. The drug maker said the benefits of Oxbryta no ...